Novavax

Mr. Robinson is responsible for process and analytical development, clinical manufacturing, QC and QA for Novavax. His team has developed a process for manufacturing recombinant virus-like particle influenza vaccine using insect cells that will use 100% single-use systems. Mr. Robinson joined Novavax after more than 20 years at sanofi pasteur, a division of the sanofi aventis group, where he most recently served as Vice President of Industrial Operations. In that capacity, Mr. Robinson was responsible for all aspects of sanofi's US sterile manufacturing operations including quality control, production planning, engineering, warehousing, outsourcing, and strategic planning. Mr. Robinson began his career at G.D. Searle & Co. as a pilot plant manager in the company's NutraSweet Division. In 1986 he joined sanofi as a vaccine production supervisor. He held various positions in manufacturing, engineering, and product development before being named vice president in 1998. He is a graduate of Lehigh University, where he earned Bachelor's and Master's degrees in chemical engineering.

Mr. Hage joined Novavax in 2004 as Vice President of Marketing and Corporate Development from CHS Incorporated, where he was an independent marketing consultant to the pharmaceutical industry. Prior to his work with CHS, Mr. Hage was the Director of Marketing at Cephalon, Inc. where his focus was on product marketing and development in the central nervous system (CNS) therapeutic area. From 1992 to 2002, Mr. Hage was with Eli Lilly and Company, most recently as Director of Marketing for Evista, Lilly's successful osteoporosis drug for post-menopausal women. During his tenure at Lilly, Mr. Hage also held various sales and marketing management positions. Mr. Hage has an MBA from The Ohio State University Fisher College of Business and a BS in Business and Economics from the University of Kentucky.

Mr. Johnston is responsible for managing Novavax’s corporate strategic planning process, evaluating potential strategic opportunities and managing select initiatives, including the GE Healthcare collaboration, for development through to proof of concept. Prior to joining Novavax, Mr. Johnston served as an executive level strategic consultant in a number of industries including biotech, financial services, and electronic security, with clients such as Novavax, RBC Bank and the U.S. Department of Homeland Security. Earlier in his career, Mr. Johnston held varying senior-level positions with a number of organizations such as Comcast, Microsoft, and Schlumberger. In each role he was able to apply a unique combination of corporate strategy, marketing and finance skills with product level and often technical skills. Tom holds an M.B.A. from The Wharton Business School and a Bachelor of Science degree in Computer Science from Arcadia University.

Director of Finance, since October 2006. Prior to joining the Company, served as Controller of Bio Veris Corporation from June 2004 through October 2006 and Controller of BioReliance Corporation between April 1998 and June 2004. Appointed as Interim Principal Accounting Officer in February 2009.

Michael McManus, Jr. became President and Chief Executive Officer of the Company in November 1999. From November 1991 to March 1999, Mr. McManus was President and Chief Executive Officer of New York Bancorp, Inc. Prior to New York Bancorp, Inc., Mr. McManus held senior positions with Jamcor Pharmaceutical, Inc., Pfizer, Inc. and Revlon Corp. Mr. McManus also spent several years as an Assistant to President Reagan. Mr. McManus serves on the Board of Directors of the following publicly traded companies: American Home Mortgage Holdings, Inc.; Liquid Audio, Inc.; Novavax, Inc.; and NWH, Inc. Mr. McManus holds a B.A. degree in Economics from the University of Notre Dame and a Juris Doctorate from Georgetown University Law Center.

During fiscal 2007, Dr. Denis O Donnell resigned from the Board and Mr. John Lambert was elected to the Board of Directors as a Class I Director and named Chairman of the Board. Mr. Gary Evans, the previous Chairman, was named Lead Independent Director. Prior to his election to the Board, Mr. Lambert had been a consultant for the Company. Mr. Lambert continues to act as a consultant to the Company. The members of the Company s Board of Directors are divided into three classes, designated Class I, Class II and Class III, each serving staggered three-year terms. The terms of the Class III directors expire at the Meeting. The terms of the Class I and Class II directors will expire at the 2008 and 2009 Annual Meetings of Stockholders, respectively. A director of any class who is elected by the Board of Directors to fill a vacancy resulting from an increase in the number of directors holds office for the remaining term of the class to which he or she is elected. A director who is elected by the Board to fill a vacancy arising in any other manner holds office for the remaining term of his or her predecessor. Directors elected by the stockholders at an annual meeting to succeed those whose terms expire at such meeting are of the same class as the directors they succeed and are elected for a term to expire at the third annual meeting of stockholders after their election and until their successors are duly elected and qualified. In the event of any increase or decrease in the authorized number of directors, the newly created or eliminated directorships must be apportioned by the Board among the three classes so as to ensure that no one class has more than one director more than any other class. However, no existing director may be reclassified from one class to another and, therefore, the number of directors in each class may become temporarily imbalanced. Two directors are to be elected at the Meeting. The Board of Directors, after recommendation by the Nominating and Corporate Governance Committee, has designated Mr. McManus and Dr. Monath as nominees for reelection as Class III directors of the Company at the Meeting. If elected, such nominees will serve until the expiration of their terms at the 2010 Annual Meeting of Stockholders and until their successors are elected and qualified. The nominees have consented to being named in this Proxy Statement and to serve if elected. The Board of Directors has no reason to believe that any nominee named herein will be unable or unwilling to serve if elected. If any nominee becomes unavailable to serve as a director, the persons named in the proxy will vote the proxy for a substitute nominee or nominees as they, in their discretion, shall determine.

Gary C. Evans is the Chairman and Chief Executive Officer and founder of GreenHunter Energy. Mr. Evans is also a principal in Global Hunter Holdings, L.P., the parent of Global Hunter Securities, LLC., entities active in both direct capital investments and investment banking activities for numerous high growth Chinese based enterprises. During twenty years ending in April 2005, Mr. Evans served as Chairman, President and Chief Executive Officer of Magnum Hunter Resources, Inc. (a New York Stock Exchange listed company) and Chairman and Chief Executive Officer of all of the Magnum Hunter subsidiaries since their formation or acquisition dating back to 1985. Mr. Evans founded the predecessor company, Hunter Resources, Inc., that was merged into and formed Magnum Hunter Resources, Inc. until its merger with Cimarex Energy, Inc. (NYSE: XEC) during June 2005 in a $2.2 billion transaction. Magnum Hunter Resources, Inc. was in the business of exploration and production of crude oil and natural gas. From 1978 to 1985, Mr. Evans was employed in the banking profession and was associated with the Mercantile Bank of Canada, where he held various positions including Vice President and Manager of the Energy Division of the Southwestern United States, and BancTexas, N.A. f/k/a/ National Bank of Commerce. Mr. Evans currently serves as the Lead Director of Novavax, Inc., a NASDAQ listed pharmaceutical company. Mr. Evans serves as an Individual Trustee of TEL Offshore Trust, a NASDAQ listed oil and gas trust. Mr. Evans also serves on the Board of Advisors of the Maguire Energy Institute at Southern Methodist University. Mr. Evans was recognized by Ernst and Young as the Southwest Area 2004 Entrepreneur of the Year for the Energy Sector and was subsequently inducted into the World Hall of Fame for Ernst & Young Entrepreneurs.